八月 2026
- Home
- Protagonist Therapeutics
八月 2026的Protagonist Therapeutics市场份额分析
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Protagonist Therapeutics(包含公司地区分支机构)
查看更多网站流量和参与度信息- protagonist-inc.com
Protagonist Therapeutics收入截至 八月 2026为 200M - 500M
Protagonist Therapeutics主要域名产生的收入
3 年中Protagonist Therapeutics主要域名的收入
Protagonist Therapeutics主要域名的收入
Protagonist Therapeutics热门域名的总访问量
了解Protagonist Therapeutics市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Protagonist Therapeutics热门域名的平均访问时长
分析Protagonist Therapeutics参与度指标。
过去 3 个月的平均访问时长
子公司明细
Protagonist Therapeutics热门域名的平均页面浏览量
了解Protagonist Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Protagonist Therapeutics 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Protagonist Therapeutics Inc. had earnings of $163M on Jul 1st '26.On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier.
九月 6, 2026阅读更多
新闻Protagonist Therapeutics Inc. sold assets to Takeda Pharmaceutical Co. in the amount of $300M on Jul 1st '24.Takeda acquired rights to rusfertide from Protagonist in 2024 for $300 million upfront.
八月 17, 2026阅读更多
新闻Protagonist Therapeutics Inc. is developing disulfide-rich peptides on Jun 1st '12.In June 2012, Zealand Pharma and Protagonist Therapeutics entered into a research collaboration agreement to develop disulfide-rich peptides (DRPs).
八月 13, 2026阅读更多
查看 Protagonist Therapeutics 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
